Do analysts prefer TAOX or RVPH?

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 16,566.67%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is TAOX or RVPH more profitable?

Synaptogenix's return on equity of -163.40% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Reviva Pharmaceuticals N/A -391.58% -119.08%

Is BRNS or RVPH more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Reviva Pharmaceuticals N/A -391.58% -119.08%

Is RVPH or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Evaxion A/S N/A -73.56% -37.45%

Reviva Pharmaceuticals (RVPH) Competitors

$0.40 0.00 (-0.02%)

As of 12:23 PM Eastern

Compare

RVPH vs. BTAI, ALGS, TAOX, BRNS, and EVAX

Should you buy Reviva Pharmaceuticals stock or one of its competitors? MarketBeat compares Reviva Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Reviva Pharmaceuticals include BioXcel Therapeutics (BTAI), Aligos Therapeutics (ALGS), Synaptogenix (TAOX), Barinthus Biotherapeutics (BRNS), and Evaxion A/S (EVAX).

How does Reviva Pharmaceuticals compare to BioXcel Therapeutics?

Reviva Pharmaceuticals (NASDAQ:RVPH) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Reviva Pharmaceuticals has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Reviva Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Reviva Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 16,566.67%. BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 1,144.34%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Reviva Pharmaceuticals is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Reviva Pharmaceuticals has higher earnings, but lower revenue than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
BioXcel Therapeutics	$640K	42.65	-$69.90M	-$5.75	N/A

In the previous week, BioXcel Therapeutics had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for Reviva Pharmaceuticals. BioXcel Therapeutics' average media sentiment score of 0.70 beat Reviva Pharmaceuticals' score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
BioXcel Therapeutics	Positive

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats BioXcel Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 726.36%. Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 16,566.67%. Given Reviva Pharmaceuticals' higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Aligos Therapeutics had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 3 mentions for Aligos Therapeutics and 0 mentions for Reviva Pharmaceuticals. Aligos Therapeutics' average media sentiment score of 0.20 beat Reviva Pharmaceuticals' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Neutral
Reviva Pharmaceuticals	Neutral

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aligos Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Reviva Pharmaceuticals has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	13.17	-$24.19M	-$8.69	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Summary

Aligos Therapeutics beats Reviva Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 16,566.67%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Reviva Pharmaceuticals has lower revenue, but higher earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$687.84K	40.89	-$28.74M	-$13.28	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Synaptogenix's return on equity of -163.40% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Synaptogenix has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Reviva Pharmaceuticals	Neutral

Summary

Reviva Pharmaceuticals beats Synaptogenix on 9 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Barinthus Biotherapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 1 mentions for Barinthus Biotherapeutics and 0 mentions for Reviva Pharmaceuticals. Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Reviva Pharmaceuticals	Neutral

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Barinthus Biotherapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 581.43%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 16,566.67%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Reviva Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.60	-$66.43M	-$1.29	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Barinthus Biotherapeutics' return on equity of -63.83% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

Reviva Pharmaceuticals beats Barinthus Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Evaxion A/S?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Evaxion A/S's return on equity of -73.56% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Evaxion A/S	N/A	-73.56%	-37.45%

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Reviva Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 16,566.67%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 279.31%. Given Reviva Pharmaceuticals' higher possible upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S has higher revenue and earnings than Reviva Pharmaceuticals. Evaxion A/S is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Evaxion A/S	$7.53M	3.21	-$7.71M	-$1.47	N/A

In the previous week, Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Evaxion A/S	Neutral

Summary

Evaxion A/S beats Reviva Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.24M	$11.50B	$6.82B	$12.97B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-0.10	791.56	279.98	25.51
Price / Sales	N/A	943.82	649.15	115.49
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	0.27	10.41	11.14	6.35
Net Income	-$19.86M	$2.80B	$3.48B	$347.60M
7 Day Performance	-5.33%	1.82%	2.39%	3.04%
1 Month Performance	-39.39%	-2.95%	-2.87%	-2.15%
1 Year Performance	-95.63%	155.26%	64.14%	21.14%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	1.8659 of 5 stars	$0.40 0.0%	$66.67 +16,566.7%	-95.4%	$5.24M	N/A	N/A	5	Gap Up
BTAI BioXcel Therapeutics	2.4034 of 5 stars	$0.87 +2.3%	$11.00 +1,168.7%	-38.1%	$26.17M	$680K	N/A	90	News Coverage Upcoming Earnings
ALGS Aligos Therapeutics	3.1615 of 5 stars	$4.08 flat	$38.50 +843.6%	-38.3%	$25.25M	$4.71M	N/A	90	Upcoming Earnings
TAOX Synaptogenix	0.3022 of 5 stars	$3.46 +5.2%	N/A	-38.9%	$24.58M	$300K	N/A	4	Positive News
BRNS Barinthus Biotherapeutics	2.2939 of 5 stars	$0.60 -0.2%	$4.00 +565.6%	-57.6%	$24.55M	N/A	N/A	107	Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. BTAI, ALGS, TAOX, BRNS, and EVAX

How does Reviva Pharmaceuticals compare to BioXcel Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Aligos Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Synaptogenix?

Summary

How does Reviva Pharmaceuticals compare to Barinthus Biotherapeutics?

Summary

How does Reviva Pharmaceuticals compare to Evaxion A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. BTAI, ALGS, TAOX, BRNS, and EVAX

How does Reviva Pharmaceuticals compare to BioXcel Therapeutics?

Which has more risk and volatility, RVPH or BTAI?

Is RVPH or BTAI more profitable?

Do analysts rate RVPH or BTAI?

Which has higher valuation and earnings, RVPH or BTAI?

Does the media favor RVPH or BTAI?

Do insiders & institutionals have more ownership in RVPH or BTAI?

Summary

How does Reviva Pharmaceuticals compare to Aligos Therapeutics?

Is ALGS or RVPH more profitable?

Do analysts recommend ALGS or RVPH?

Does the media refer more to ALGS or RVPH?

Do institutionals & insiders have more ownership in ALGS or RVPH?

Which has more volatility and risk, ALGS or RVPH?

Which has better earnings & valuation, ALGS or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Synaptogenix?

Do analysts prefer TAOX or RVPH?

Which has higher valuation & earnings, TAOX or RVPH?

Is TAOX or RVPH more profitable?

Which has more risk & volatility, TAOX or RVPH?

Do institutionals and insiders have more ownership in TAOX or RVPH?

Does the media refer more to TAOX or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Barinthus Biotherapeutics?

Which has more risk & volatility, BRNS or RVPH?

Does the media refer more to BRNS or RVPH?

Do insiders and institutionals have more ownership in BRNS or RVPH?

Do analysts rate BRNS or RVPH?

Which has higher earnings & valuation, BRNS or RVPH?

Is BRNS or RVPH more profitable?

Summary

How does Reviva Pharmaceuticals compare to Evaxion A/S?

Is RVPH or EVAX more profitable?

Do institutionals and insiders hold more shares of RVPH or EVAX?

Which has more risk & volatility, RVPH or EVAX?

Do analysts prefer RVPH or EVAX?

Which has better valuation & earnings, RVPH or EVAX?

Does the media prefer RVPH or EVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools